Sumiko Yoshida

Sumiko Yoshida

Auto-generated profile, based on publicly available information

Sumiko Yoshida

Medical Genome Center (N.I., S.Y.), National Center of Neurology and Psychiatry, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2017 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
SYShusuke Yagi
Shusuke Yagi
Ken-ichi AiharaKen-ichi Aihara
Ken-ichi Aihara
TKTakeshi Kondo
Takeshi Kondo
KKKiyoe Kurahashi
Kiyoe Kurahashi
SYSumiko Yoshida
Sumiko Yoshida
MSMasataka Sata
Masataka Sata

1 May 2019 in Heliyon
Verified
Journal Article
Open access
LGLeo Gotoh
Leo Gotoh
MYMisa Yamada
Misa Yamada
KHKotaro Hattori
Kotaro Hattori
DSDaimei Sasayama
Daimei Sasayama
TNTakamasa Noda
Takamasa Noda
MYMitsuhiko Yamada
Mitsuhiko Yamada
Major depressive disorder (MDD) is the most common psychiatric disorders. However, a biochemical marker has yet to be established for clinical purposes. It is proposed that lysophosphatidic acid (LPA, 1-acyl-2-sn-glycerol-3-phosphoate) plays some important roles in emotional regulation of experimental animals. Therefore, in this study, we measured LPA levels using enzyme-linked immunosorbent assays of cerebrospinal fluid (CSF) and plasma samples from patients with MDD. The participants were 52 patients and 49 normal healthy controls for CSF study, and 47 patients and 44 controls for plasma study. We used the Japanese version of the GRID Hamilton Depression Rating Scale (17-item version) for the assessment of depressive symptoms. We found no associations between LPA levels (CSF or plasma) and either diagnosis or severity of MDD, or with psychotropic medication. In conclusion, our data suggest that LPA levels likely would not serve as a practical biomarker of MDD.

30 May 2023 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
RYRisa Yamada
Risa Yamada
TFTakeshi Fujii
Takeshi Fujii
KHKotaro Hattori
Kotaro Hattori
HHHiroaki Hori
Hiroaki Hori
RMRyo Matsumura
Ryo Matsumura
HKHiroshi Kunugi
Hiroshi Kunugi
Risa Yamada, Takeshi Fujii, Kotaro Hattori, Hiroaki Hori, Ryo Matsumura, Tomoko Kurashimo, Naoko Ishihara, Sumiko Yoshida, Tomiki Sumiyoshi, Hiroshi Kunugi. Clin Psychopharmacol Neurosci 2023;21:296-303. https://doi.org/10.9758/cpn.2023.21.2.296

1 January 2022 in The Journal of Medical Investigation
Verified
Journal Article
Open access
PDF file
YMYukari Mitsui
Yukari Mitsui
YIYuto Iizuka
Yuto Iizuka
TTTomoaki Tanaka
Tomoaki Tanaka
THTomoyo Hara
Tomoyo Hara
SMShiho Masuda
Shiho Masuda
IEItsuro Endo
Itsuro Endo
Objective : To examine diagnostic performance of corticotropin-releasing hormone (CRH) test combined with baseline dehydroepiandrosterone sulfate (DHEA-S) in patients with a suspect of central adrenal insufficiency. Methods : Patients (n=215) requiring daily or intermittent hydrocortisone replacement, or no replacement were retrospectively checked with their peak cortisol after CRH test and baseline DHEA-S. Results : None of 106 patients with the peak cortisol ≥ 17.5 µg / dL after CRH test required replacement, and all 64 patients with the peak cortisol < 10.0 µg / dL required daily replacement. Among 8 patients with 10.0 µg / dL ≤ the peak cortisol < 17.5 µg / dL and baseline DHEA-S below the reference range, 6 patients required daily replacement and 1 patient was under intermittent replacement. Among 37 patients with 10.0 µg / dL ≤ the peak cortisol < 17.5 µg / dL and baseline DHEA-S within the reference range, 10 and 6 patients were under intermittent and daily replacement, respectively. Conclusions : No patients with the peak cortisol ≥ 17.5 µg / dL required hydrocortisone replacement, and all patients with the peak cortisol below 10.0 µg / dL required daily replacement. Careful clinical evaluation was required to determine requirement for replacement in patients with 10.0 µg / dL ≤ the peak cortisol < 17.5 µg / dL even in combination with baseline DHEA-S. J. Med. Invest. 69 : 287-293, August, 2022

9 November 2023 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
HMHiroyuki Maki
Hiroyuki Maki
MMMadoka Mori-Yoshimura
Madoka Mori-Yoshimura
HMHiroshi Matsuda
Hiroshi Matsuda
YHYasumasa Hashimoto
Yasumasa Hashimoto
MOMiho Ota
Miho Ota
NSNoriko Sato
Noriko Sato
BACKGROUND AND PURPOSE: Although various neuropsychological problems in Becker muscular dystrophy have attracted attention, there have been few related neuroimaging studies. We investigated brain abnormalities in patients with Becker muscular dystrophy using 3D T1WI and DTI. MATERIALS AND METHODS: MR images were obtained for 30 male patients and 30 age-matched healthy male controls. We classified patients into Dp140+ and Dp140− subgroups based on their predicted dystrophin Dp140 isoform expression and performed voxel-based comparisons of gray and white matter volumes and DTI metrics among the patients, patient subgroups, and controls. ROI-based DTI analyses were also performed. RESULTS: Significantly decreased fractional anisotropy was observed in the left planum temporale and right superior parietal lobule compared between the Becker muscular dystrophy and control groups. In the Dp140− subgroup, decreased fractional anisotropy was observed in the left planum temporale, but no significant changes were seen in the Dp140+ subgroup. The ROI-based analysis obtained the same results. No significant differences were evident in the gray or white matter volumes or the DTI metrics other than fractional anisotropy between the groups. CONCLUSIONS: A DTI metric analysis is useful to detect white-matter microstructural abnormalities in Becker muscular dystrophy that may be affected by the Dp140 isoform expression.

1 June 2010 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
Yasumasa IkedaYasumasa Ikeda
Yasumasa Ikeda
KAKen-Ichi Aihara
Ken-Ichi Aihara
MAMasashi Akaike
Masashi Akaike
TSTakashi Sato
Takashi Sato
KIKazue Ishikawa
Kazue Ishikawa
TMToshio Matsumoto
Toshio Matsumoto
Doxorubicin (Dox) has been used as a potent anticancer agent, but serious cardiotoxicity precludes its use in a wide range of patients. We have reported that the androgen-androgen receptor (AR) system plays important roles in cardiac growth and protection from angiotensin II-induced cardiac remodeling. The present study was undertaken to clarify whether the androgen-AR system exerts a cardioprotective effect against Dox-induced cardiotoxicity. Male AR knockout (ARKO) and age-matched littermate male wild-type (WT) mice at 25 wk of age were given ip injections of Dox (20 mg/kg) or a vehicle. The survival rate and left ventricular function in Dox-treated male ARKO mice were reduced compared with those in Dox-treated male WT mice. Electron microscopic study showed prominent vacuole formation of myocardial mitochondria in Dox-treated male ARKO mice. Cardiac oxidative stress and apoptosis of cardiomyocytes were increased more prominently by Dox treatment in male ARKO mice than in male WT mice. In addition, Dox-induced reduction in the expression of cardiac mitochondria transcription factor A (Tfam) and phosphorylation of serine-threonine kinase (Akt) was more pronounced in male ARKO mice than in male WT mice. In cardiac myoblast cells, testosterone up-regulated Akt phosphorylation and Tfam expression and exerted an antiapoptotic effect against Dox-induced cardiotoxicity. Collectively, the results demonstrate that Dox-induced cardiotoxicity is aggravated in male ARKO mice via exacerbation of mitochondrial damage and superoxide generation, leading to enhanced apoptosis of cardiomyocytes. Thus, the androgen-AR system is thought to counteract Dox-induced cardiotoxicity partly through activation of the Akt pathway and up-regulation of Tfam to protect cardiomyocytes from mitochondrial damage and apoptosis.